Advertise on podcast: The Research Evangelist

I sat down with Dr. Tony Mok to tell us what we need to know about the seven year update of the Phase 3 CROWN study for advanced ALK-positive non-small cell lung cancer (NSCLC) presented at ASCO. Send us Fan Mail researchevangelist.com

I sat down with Dr. Sarah Goldberg to talk about the COPERNICUS Study for patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC) abstract she presented at ASCO. Send us Fan Mail researchevangelist.com

I sat down with Dr. Melissa Johnson, one of the authors of the Phase 3 LIBRETTO-432 Trial abstract presented at ASCO. Send us Fan Mail researchevangelist.com

I sat down with Dr. Yasir Elamin to get his thoughts on his presentation at ASCO regarding patient reported outcomes and health-related quality of life with Taletrectinib in advanced ROS1 non-small cell lung cancer (NSCLC)  from the TRUST-II Study. Send us Fan Mail researchevangelist.com

I sat down with Professor Sanjay Popat to get his thoughts on the ROSETTA Lung-02 abstract presented at ASCO and what it could mean for clinical practice, future research, and patient care. Send us Fan Mail researchevangelist.com

I sat down with Dr. Nasser H. Hanna to get his thoughts on three lung cancer research abstracts presented at ASCO that he is most excited about, and what they could mean for clinical practice, future research, and patient care. Send us Fan Mail researchevangelist.com

On today’s episode, meet Dr. Fawzi Abu Rous, a thoracic medical oncologist at Henry Ford Health in Detroit, Michigan. Dr. Abu Rous earned his MD from the University of Jordan Faculty of Medicine in 2015. He completed his residency at Michigan State University and graduated from his Hematology and Oncology Fellowship at Henry Ford Health. Dr. Abu Rous conducts research on lung cancer, specializing in developing biomarkers to guide treatment decisions. He is dedicated to providing the same level of care to his patients as he would to his own family and loved ones. Send us Fan Mail researchevangelist.com

On today's episode meet Dr. Hina Khan. Dr. Khan is a medical oncologist who specializes in thoracic cancers and is an Assistant Professor at the Warren Alpert Medical School at Brown University. She practices at Rhode Island, The Miriam and Newport hospitals and she is board certified in internal medicine, hematology and oncology. Dr. Khan received her medical degree from the Jawaharlal Nehru Medical College, did her residency at Mt. Sinai School Of Medicine and her fellowship at Albert Einstein College Of Medicine at Montefiore Medical Center.  Send us Fan Mail researchevangelist.com

On today's episode meet Lori Sakoda. Lori is a research scientist in the Division of Research at Kaiser Permanente Northern California, and Associate Professor of Health Systems Science at the Kaiser Permanente Bernard J. Tyson School Of Medicine. Her research interests currently encompass identifying genetic and environmental determinants of risk in prognoses for cancer, particularly of lung cancer. Lori received her Master of Public Health and Epidemiology degrees from the University of California Berkeley, and her PhD in Epidemiology from the University of Washington. Send us Fan Mail researchevangelist.com

On today's episode meet Dr. Joshua Bauml. Dr. Bauml is the Lung Cancer Disease Area Stronghold Leader at Johnson & Johnson Innovative Medicine... Send us Fan Mail researchevangelist.com

On today’s episode, meet Dr. Eric Singhi. Dr. Singhi is the Assistant Professor of both the Department General Oncology Division of Cancer Medicine and the Department of Thoracic Head and Neck Medical Oncology at the University of Texas MD Anderson Cancer Center in Houston. He received his medical degree at the Medical University of South Carolina. He completed his clinical residency at Vanderbilt and his fellowship at MD Anderson. Send us Fan Mail researchevangelist.com

On today’s episode, meet Biljana Naumovic. Biljana is the President of U.S. Oncology, Solid Tumor at  Johnson & Johnson, where she is spearheading innovative cancer  treatments and advocating for equity in healthcare.   She is committed to advancing the  organization’s solid tumor portfolio and pipeline, spanning prostate,  bladder, and lung cancer, as well as multiple novel treatment pathways.  Biljana is passionately focused on bringing medical innovation  and ultimately transforming patient care.  Biljana is a physician by training  and graduated in 2001 from the Belgrade University Medical School. She  worked as a practicing physician for several years before transitioning  to industry. She also holds an executive education degree  from the London Business School. Send us Fan Mail researchevangelist.com